Biotech Values

[ThomasS]

VRTX: Vertex Reports 52% SVR 12 Rate for a 24-week Telaprevir-based Regimen in Genotype 1 Hepatitis C Patients Who Failed Prior Treatment
Monday June 9, 7:30 am ET
-- 73% of prior relapsers achieved SVR12 with 24-week telaprevir-based treatment
-- 41% of prior non-responders achieved SVR12 with 24-week telaprevir-based regimen

http://biz.yahoo.com/bw/080609/20080609005508.html?.v=1


"Three may keep a secret, if two of them are dead."
- B. Franklin

"He has all the virtues I dislike and none of the vices I admire."
- Sir Winston Churchill